![]() |
|
|
Vol. 62, Issue 3, 602-607, September 2002
Department of Pharmacology (L.L., I.M., Y.S., J.K.), First Department of Internal Medicine (T.I., K.Y., Y.M.), School of Medicine, and Department of Ecology and Clinical Therapeutics, School of Nursing (Y.W.), Fukushima Medical University, Fukushima, Japan
| |
Abstract |
|---|
|
|
|---|
Using the whole-cell voltage-clamp method, we investigated the effect of fluvastatin, a 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor, on lysophosphatidylcholine (LPC)-induced nonselective cation current (INSC) in guinea pig cardiac ventricular myocytes. External LPC (3~50 µM) induced INSC in a dose-dependent manner with a lag. With fluvastatin (5 µM) in the external solution, LPC induced INSC, which was significantly smaller and with a longer lag compared with that in the absence of fluvastatin. With mevalonic acid (MVA) (100 µM) in the external solution, fluvastatin did not diminish LPC-induced INSC. Geranylgeranylpyrophosphate, an MVA metabolite, in the pipette solution prevented fluvastatin from diminishing LPC-induced INSC, suggesting that isoprenylated signaling molecules, such as the small G-protein Rho, might be involved in the LPC effect. Botulinum toxin C3, Rho-kinase inhibitor (R)-(+)-trans-N-(4-pyridyl)-4-(1-aminoethyl)-cyclohexanecarboxamide, 2 HCl (Y-27632), or pertussis toxin in the pipette solution suppressed LPC-induced INSC. We conclude that LPC induces INSC via a Gi/Go-coupled receptor and Rho-mediated pathway. The inhibitory effect of fluvastatin on LPC-induced INSC provides a new insight into the signal transduction mechanism and may have important clinical implications.
| |
Introduction |
|---|
|
|
|---|
L-
-Lysophosphatidylcholine
(palmitoyl) (LPC) is an amphipathic metabolite of membrane
phosphatidylcholine; high concentrations of LPC have been found in
ischemic hearts (Sobel et al., 1978
; Shaikh and Downer, 1981
; Corr et
al., 1982
; Otani et al., 1989
; Sedlis et al., 1990
). LPC applied
externally increases intracellular Ca2+
concentration ([Ca2+]i)
in isolated cardiac myocytes (Sedlis et al., 1983
; Woodley et al.,
1991
; Ver Donck et al., 1992
; Hashizume and Abiko, 1996
). Therefore,
LPC is thought to be one of the causes of Ca2+
overload and arrhythmia during cardiac ischemia and reperfusion (Hoque
et al., 1995
; Hashizume et al., 1998
). Magishi et al. (1996)
reported
that exogenous LPC induces a nonselective cation current (INSC) in cardiac myocytes, but the mechanism
involved has not been elucidated.
Recently, Yokoyama et al. (2002)
found that LPC increases
[Ca2+]i and membrane
current in cultured human endothelial cells in a manner similar to that
found in cardiac myocytes. Furthermore, they found that
3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors such as
fluvastatin, cerivastatin, and pravastatin inhibit the LPC-induced
increase in [Ca2+]i.
HMG-CoA reductase inhibitors prevent the synthesis of mevalonic acid
(MVA) from HMG-CoA, thereby reducing cholesterol synthesis. Therefore,
it is used clinically to prevent the development of atherosclerosis.
Recently, it has been shown that MVA is not only a precursor of
cholesterol but also of numerous metabolites that are involved in
important cell functions, including endothelial function, inflammatory
responses, plaque stability, and thrombus formation (Corsini et al.,
1999
). We tested fluvastatin in cardiac myocytes and found that it
inhibited LPC-induced INSC in guinea pig
ventricular myocytes. We investigated the mechanism of LPC-induced INSC by using fluvastatin under the whole-cell
voltage clamp.
| |
Methods |
|---|
|
|
|---|
Isolation of Cells.
All experiments were performed according
to the regulations of the Animal Research Committee of Fukushima
Medical University. Single cardiac ventricular cells were isolated
essentially by the method of Yazawa et al. (1990)
. Guinea pigs weighing
250 to 400 g were anesthetized by intraperitoneal injection of
pentobarbital (30 mg/kg). The chest was opened under artificial
ventilation, the aorta was cannulated in situ, and the heart was
removed. Blood was washed out with Tyrode-HEPES solution and the heart
was mounted in a Langendorff perfusion system. Tyrode-HEPES solution
contained 140 mM NaCl, 5.4 mM KCl, 1.8 mM CaCl2,
1 mM MgCl2, 0.33 mM
NaH2PO4, 5.5 mM glucose,
and 5 mM HEPES, pH 7.4. The perfusate was changed to
Ca2+-free Tyrode solution to stop the heartbeat
and then to one containing 0.01% (w/v) collagenase (Wako, Osaka,
Japan) and 0.002% (w/v) alkaline protease (Nagase, Tokyo, Japan).
After about 20 min, the collagenase solution was washed out by
perfusing with a
high-K+/low-Cl
solution
[modified KB solution (Isenberg and Klöckner, 1982
)]. The
modified KB solution contained 70 mM KOH, 50 mM l-glutamic acid, 40 mM KCl, 20 mM taurine, 20 mM
KH2PO4, 3 mM
MgCl2, 10 mM glucose, 0.2 mM EGTA, and 10 mM
HEPES, pH 7.2. Incisions were made in the cardiac ventricular tissue in
the modified KB solution and the tissue was shaken gently to isolate
the cells. The cell suspension was stored at 4°C for later use.
Patch-Clamp Recording.
Membrane currents were recorded
by the whole-cell patch-clamp method using pCLAMP (ver. 8.0, Axon
Instruments, Union City, CA) and custom RAM5 software and patch-clamp
amplifiers [TM-1000 (ActME, Tokyo, Japan) and EPC-7 (List, Darmstadt,
Germany)]. Single cardiac ventricular cells were placed in a recording
chamber (0.5-ml volume) attached to an inverted microscope (Nikon
ECLIPSE TE200, Tokyo, Japan) and superfused with the Tyrode solution at
a rate of 5 ml/min. The temperature of the bath solution was maintained at 35 ± 0.5°C with a water jacket. Patch pipettes were forged from 1.5-mm diameter glass capillaries (Nihon Rikagaku Kikai, Tokyo,
Japan) with a microelectrode puller (pp-83; Narishige, Tokyo, Japan).
The pipette resistance was 2~4 M
when filled with the pipette
solution. The pipette solution contained 120 mM CsOH, 20 mM CsCl, 60 mM
aspartic acid, 3 mM MgCl2, 5 mM MgATP, 10 mM BAPTA, and 20 mM HEPES, pH 7.2, with aspartic acid.
BaCl2 (0.5 mM) in Tyrode solution was added to
block K+ currents. The series resistance was
compensated. Current signals were filtered at a 2.5-kHz bandwidth and
were stored on a PC (XPS T450; Dell Computer Corp., Round Rock, TX).
60 mV to 60 mV, then hyperpolarized to
110 mV and depolarized back to the holding
potential at a speed of 680 mV/s. The descending limb of the ramp was
used to plot the I-V curve without capacitative current compensation.
Analog recordings of current and voltage were made with a chart
recorder (W1-641G; Nihon Kohden, Japan) in one of the two apparatus
used (for Figs. 3A, 5A, and 7A). Current recordings were made digitally
in another apparatus so that long-time current records were reproduced
digitally using pCLAMP software (Figs. 1A, 2A, and 6A).
Drugs.
LPC (Sigma-Aldrich, St. Louis, MO) was dissolved in
chloroform to make a 1 mM stock solution, which was evaporated to
dryness under a stream of N2 gas and stored at
20 °C. After thawing the LPC was diluted to appropriate
concentrations with the external solution. DL-Mevalonic
acid lactone, geranylgeranylpyrophosphate (GGP) and Clostridium
botulinum C3 exoenzyme (C3) were purchased from Sigma-Aldrich.
Fluvastatin was a kind gift from Novartis (Basel, Switzerland) and
Y-27632, a Rho kinase inhibitor, was from Welfide (Osaka, Japan).
Data Analysis. All the values are presented as mean ± S.E. (number of experiments). Student's t test and analysis of variance were used for statistical analyses. P values less than 0.05 were considered significant. The concentration-response data were fitted and IC50 and Hill coefficient values were obtained using Delta Graph Professional (Polaroid Computing, Tokyo, Japan).
| |
Results |
|---|
|
|
|---|
Effects of LPC on Membrane Current.
Figure
1 shows the effect of 10 µM LPC on the
membrane current in a ventricular myocyte. LPC in the external solution
induced INSC with a lag and it did not increase
steadily but oscillated. The current response was reversible and the
second application of 10 µM LPC induced INSC
with an amplitude similar to the first application. The lag before
inducing INSC was longer after the first than the
second application. The control I-V curves before the application of
LPC and the largest current induced by 10 µM LPC are plotted in Fig.
1, B and C. The LPC-induced current crossed with the control at 0 mV,
confirming that the LPC-induced current is INSC
(Magishi et al., 1996
).
|
Effect of Fluvastatin on LPC-Induced INSC.
Figure
2 shows the effect of fluvastatin on
LPC-induced current. As shown in Fig. 1, repetitive application of LPC
induces INSC with each application. However, as
shown in Fig. 2, the initial application of 10 µM LPC induced
INSC in the absence of fluvastatin but did not in
response to the second application of LPC, when 5 µM fluvastatin was
present in the external solution. After washing out fluvastatin, LPC
again induced INSC (not shown). These results indicate that fluvastatin reversibly inhibits LPC-induced
INSC. When fluvastatin was applied after
INSC had developed in response to LPC, it did not
inhibit the current (not shown), indicating that fluvastatin does not
directly inhibit INSC channels.
|
Effect of MVA on LPC-Induced Current.
If fluvastatin inhibited
LPC-induced INSC by inhibiting HMG-CoA reductase,
MVA should prevent this effect of the drug and this was examined in the
experiment shown in Fig. 3 in which 100 µM MVA was perfused in the
external solution for 3 min before adding 5 µM fluvastatin. In the
presence of MVA and fluvastatin, 10 µM LPC induced
INSC. The I-V curve of the current induced by LPC
(Fig. 3B, d) was identical to that
induced in the absence of the two agents. This result indicates that
fluvastatin inhibits LPC as a result of its inhibition of an HMG-CoA
reductase.
|
|
Involvement of Geranylgeranylpyrophosphate.
Geranylgeranylpyrophosphate (GGP) is a downstream isoprenoid product of
MVA in the cholesterol synthesis pathway (Glomset et al., 1990
). To
pursue the mechanism of LPC-induced INSC further, GGP was included in the pipette solution and the effect of fluvastatin was examined. Inclusion of GGP alone did not induce
INSC. Fluvastatin did not inhibit
INSC induced by 10 µM LPC in the presence of
GGP (Fig. 5). This indicates that GGP is
necessary for the current induction by LPC. Because GGP is necessary
for membrane association of the small GTP binding protein, Rho
(Goldstein and Brown, 1990
; Maltese, 1990
; Ridley and Hall, 1992
), this
result suggests the possible involvement of Rho in the effect of LPC.
|
Effect of C3 Exoenzyme on LPC-Induced INSC.
Rho is
selectively inactivated by C3 through ADP-ribosylation (Sah et al.,
2000
). To assess whether Rho is involved in the effect of LPC, we
included 4 µg/ml C3 in the pipette solution and applied LPC (Fig.
6). LPC did not induce any significant
change in current in the presence of C3 whether or not MVA was present in the bath solution (Fig. 6, B and C). Heat-inactivated C3 did not
inhibit LPC-induced current. These results indicate that the small GTP
binding protein Rho is involved in the process of LPC-induced INSC.
|
Effect of a Rho-Kinase Inhibitor on LPC-Induced Current.
Y-27632 is a selective inhibitor of Rho-kinase (Uehata et al., 1997
).
Because Rho may activate Rho-kinase in the process of LPC-induced
INSC, we tested the effect of LPC with 10 µM
Y-27632 in the pipette solution. Figure 7
shows that LPC induced INSC, but it was
significantly smaller and the lag was longer in the presence of Y-27632
than in its absence.
|
|
Effect of Pertussis Toxin on LPC-Induced Current.
To examine
the possible involvement of heterotrimeric G-proteins in the
LPC-mediated pathway, pertussis toxin, an inhibitor of
Gi/Go, was included in the
pipette solution. In the presence of pertussis toxin (1 µg/ml), the
LPC (10 µM)-induced current was 1.62 pA/pF (n = 4) at
100 mV (figure not shown). This was significantly smaller than that
of the control, indicating that the Gi/Go-coupled membrane receptor is
involved in the LPC-mediated pathway.
| |
Discussion |
|---|
|
|
|---|
In this study, we demonstrated that LPC induces
INSC in guinea pig ventricular myocytes through a
mechanism that involves an activation of the small G-protein Rho. The
LPC-induced effect must be mediated by a receptor that interacts with
the PTX sensitive G-proteins. Figure 9
shows a proposed signal transduction pathway for LPC-induced
INSC based on our results.
|
LPC activated INSC in a concentration-dependent
manner with an EC50 of approximately 20 µM.
There was a lag before the development of INSC
with an average of 115 ± 32 s (n = 10) with
10 µM LPC, and it was shortened to 40 ± 11 s
(n = 7) with 30 µM LPC, suggesting that the induction
of INSC by LPC involves a distinct signal
transduction process that takes a few minutes. We demonstrated that
fluvastatin, a HMG-CoA reductase inhibitor, inhibited LPC-induced
INSC. Fluvastatin inhibits MVA synthesis from
HMG-CoA. With MVA in the external solution, fluvastatin did not inhibit
LPC-induced iNSC. Therefore, it seems that MVA is
essential for the induction of INSC by LPC. Recently, it has been shown that the MVA-derived isoprenoids, GGP and
farnesylpyrophosphate, modify several proteins by covalent attachment
or prenylation, which is necessary for their association with membranes
and thus for their function (Glomset et al., 1990
; Goldstein and Brown,
1990
; Maltese, 1990
). When GGP was included in the pipette solution,
fluvastatin did not inhibit LPC-induced INSC.
Therefore, it seems that some protein that is isoprenylated by GGP is
involved in the LPC effect. Candidate proteins for isoprenylation by
GGP are Rho, Rac, Cdc42, Rab, Rap, and the
-subunit of
heterotrimeric G-proteins (Corsini et al., 1999
). As shown in Fig. 6,
botulinum toxin C3 exoenzyme, but not heat-inactivated C3, in the
pipette solution almost completely inhibited LPC-induced
INSC. C3 is an ADP-ribosyltransferase that
inactivates Rho subfamily proteins (RhoA, RhoB, and RhoC) more
specifically than other small GTP binding proteins, such as Rac or
Cdc42 (Ridley and Hall, 1992
). The result with C3 indicates that Rho is
involved in the induction of INSC by LPC (Fig.
9).
Many effectors of Rho-binding proteins have been identified but
the best characterized are Rho kinases, which are serine/threonine directed and include Rho kinase/ROK
/Rock-II and p160ROCK/ROCK
(Sah et al., 2000
). Y-27635 specifically inhibits Rho-kinase Rock, by
competing for ATP binding (Uehata et al., 1997
). Y-27635 at 10 µM
inhibited LPC-induced INSC significantly but not
completely (Fig. 8), indicating that Rho-kinase might be involved in
the effect of LPC (Fig. 9).
LPC may stimulate some membrane receptor through which a signal
transduction pathway is activated and this pathway requires Rho and
Rock to open INSC channels. In this study, PTX
inhibited the effect of LPC, indicating that guinea pig ventricular
myocytes possess an LPC-receptor that is coupled to the pertussis
toxin-sensitive heterotrimeric G-protein,
Gi/Go (Fig. 9). Recently,
two G-protein-coupled orphan receptors, G2A (Kabarowski et al., 2001
)
and GPR4 (Zhu et al. 2001
), were identified as the LPC receptors. Both
of these receptors are coupled to the PTX-sensitive G protein, and
mediate the LPC-induced increase in intracellular
Ca2+ concentration. In addition, GPR4 was shown
to be expressed in the heart, and its effects were inhibited by both
PTX and botulinus toxin C3 (Zhu et al. 2001
). Involvement of GPR4
and/or G2A in LPC-induced INSC should be
investigated in cardiac ventricular cells.
G-protein-coupled lysophopholipid receptors have also been found
for sphingosine-1-phosphate (SPP), sphingosylphosphocholine, and
lysophosphatidic acid (Fukushima et al., 2001
). Bünemann et al.
(1995)
found that SPP activates IK(Ach) in guinea
pig atrial myocytes via Gi-coupled receptors. Recently, they detected
Edg1, Edg3, Edg5, and Edg8 mRNAs and OGR1 lysophospholipid receptor protein in rat atrium and ventricle (Liliom et al., 2001
). More recently, Muraki and Imaizumi (2001)
succeeded in recording
PTX-sensitive nonselective cation channels induced by SPP in human
endothelial cells.
Some important questions about the LPC-induced signal transduction
pathway need to be addressed. One is how LPC activates the Rho
signaling pathway. Although G12
and
G13
have recently been identified as the
G-proteins that transduce signals from various receptors to the Rho
GTPase by stimulating the GDP-GTP exchange, our results suggest that
certain PTX-sensitive G-proteins can initiate the Rho signaling pathway
in a GGP-dependent manner. Because GGP alone did not induce
INSC, it seems that LPC triggers geranylgeranylation of Rho. It is important to identify what types of
PTX-sensitive G-proteins and which of the
- or 
-subunits are
associated with the LPC receptors.
Another important question is how fluvastatin affects the
intracellular levels of GGP so rapidly (i.e., within a few minutes). It
has already been demonstrated that inhibition of HMG-CoA reductase by
statins blocks the Rho-dependent cellular responses by preventing isoprenyl modification of Rho. However, this effect of statin was
generally observed between 6 and 24 h (Laufs and Liao, 1998
). The
present results demonstrated that the inhibition of LPC-induced INSC by statin was very rapid, occurring within a
few minutes. Furthermore, mevalonate or GGP prevented the inhibitory
effect of statin, suggesting that statin exerted its effect by lowering intracellular GGP. We recently demonstrated similar results with LPC-induced INSC in human aortic endothelial
cells (Yokoyama et al, 2002
). In the endothelial cells, LPC-induced
INSC was accompanied by a rapid translocation of
GTP-bound RhoA into membrane within one min. Furthermore, a brief
treatment with fluvastatin (3 min) prevented the LPC-induced
INSC and translocation of RhoA to the membrane.
This effect of statin also disappeared in the presence of MVA or GGP.
These results suggest that LPC stimulates INSC through a similar mechanism in both ventricular myocytes and
endothelial cells. Given these results, we suggest that, at least in
these cells, intracellular GGP levels may be controlled dynamically through metabolic processes. Further studies with direct measurements of intracellular GGP levels are required to evaluate our hypothesis.
Fluvastatin and various other statins are used clinically for hyperlipidemia to lower serum cholesterol levels. There are increasing reports on various effects of statins. The inhibitory effect of fluvastatin on LPC-induced INSC provides a new insight into the signal transduction mechanism and may have important clinical implications.
| |
Acknowledgments |
|---|
We highly appreciate the technical assistance of Sanae Sato and Dr. Tomoyuki Ono.
| |
Footnotes |
|---|
Received January 28, 2002; Accepted May 17, 2002
1 Current address: Department of Pathophysiology, Basic Nursing, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Japan.
This work was supported by grants-in-aid for Scientific Research 11670096 and 11357020 from the Japan Foundation for Promotion of Science. L.L. is the recipient of a scholarship from the Heiwa Nakajima Foundation. Y.S. was a 4th year medical student at the time of the experiments.
Address correspondence to: Dr. Junko Kimura, Department of Pharmacology, School of Medicine, Fukushima Medical University, Fukushima 960-1295 Japan. E-mail: jkimura{at}fmu.ac.jp
| |
Abbreviations |
|---|
LPC, L-
-lysophosphatidylcholine (palmitoyl);
INSC, nonselective cation current;
HMG, 3-hydroxy-3-methylglutaryl;
MVA, mevalonic acid;
KB, Kraftsbrühe;
BAPTA, (1,2-bis(2-aminophenoxy)-ethane-N,N,N',N'-tetraacetic
acid;
I-V, current-voltage;
GGP, geranylgeranylpyrophosphate;
C3, Clostridium botulinum C3 exoenzyme;
Y-27632, (R)-(+)-trans-N-(4-pyridyl)-4-(1-aminoethyl)-cyclohexanecarboxamide,
2 HCl;
ROCK, Rho-associated coiled-coil-forming protein kinase;
PTX, pertussis toxin;
SPP, sphingosine-1-phosphate.
| |
References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
K. Sakamoto, T. Honda, S. Yokoya, S. Waguri, and J. Kimura Rab-small GTPases are involved in fluvastatin and pravastatin-induced vacuolation in rat skeletal myofibers FASEB J, December 1, 2007; 21(14): 4087 - 4094. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Pochynyuk, J. D. Stockand, and A. Staruschenko Ion Channel Regulation by Ras, Rho, and Rab Small GTPases Experimental Biology and Medicine, November 1, 2007; 232(10): 1258 - 1265. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Maeda, I. Matsuoka, T. Iwamoto, H. Kurose, and J. Kimura Down-Regulation of Na+/Ca2+ Exchanger by Fluvastatin in Rat Cardiomyoblast H9c2 Cells: Involvement of RhoB in Na+/Ca2+ Exchanger mRNA Stability Mol. Pharmacol., August 1, 2005; 68(2): 414 - 420. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Staruschenko, A. Nichols, J. L. Medina, P. Camacho, N. N. Zheleznova, and J. D. Stockand Rho Small GTPases Activate the Epithelial Na+ Channel J. Biol. Chem., November 26, 2004; 279(48): 49989 - 49994. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||